Community Engagement in Vaccination Promotion: Systematic Review and Meta-Analysis (Preprint)
Authors: Xie Yao Jie , Liao Xiaoli , Lin Meijuan , Yang Lin , Cheung Kin , Zhang Qingpeng , Li Yan , Hao Chun , Wang Harry HX , Gao Yang , Zhang Dexing , Molassiotis Alex , Siu Gilman Kit Hang , Leung Angela Yee Man 
Published: May 2024

BACKGROUND

Community engagement plays a vital role in global immunization strategies, offering the potential to overcome vaccination hesitancy and enhance vaccination confidence. Although there is significant backing for community engagement in health promotion, the evidence supporting its effectiveness in vaccination promotion is fragmented and of uncertain quality.

OBJECTIVE

This review aims to systematically examine the effectiveness of different contents and extent of community engagement for promoting vaccination rates.

METHODS

This study was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A comprehensive and exhaustive literature search was performed in 4 English databases (PubMed, Embase, Web of Science, and Cochrane Library) and 2 Chinese databases (CNKI and Wan Fang) to identify all possible articles. Original research articles applying an experimental study design that investigated the effectiveness of community engagement in vaccination promotion were eligible for inclusion. Two reviewers independently performed the literature search, study selection, quality assessment, and data extraction. Discrepancies were resolved through discussion, with the arbitration of a third reviewer where necessary.

RESULTS

A total of 20 articles out of 11,404 records from 2006 to 2021 were retrieved. The studies used various designs: 12 applied single-group pre-post study designs, 5 were cluster randomized controlled trials (RCTs), and 3 were non-RCTs. These studies targeted multiple vaccines, with 8 focusing on children’s immunization, 8 on human papillomavirus vaccine, 3 on hepatitis B virus vaccine, and 1 on COVID-19 vaccine. The meta-analysis revealed significant increases in vaccination rates both in pre-post comparison (rate difference [RD] 0.34, 95% CI 0.21-0.47, <i>I</i><sup>2</sup>=99.9%, <i>P</i>&lt;.001) and between-group comparison (RD 0.18, 95% CI 0.07-0.29, <i>I</i><sup>2</sup>=98.4%, <i>P</i>&lt;.001). The meta-analysis revealed that participant recruitment had the largest effect size (RD 0.51, 95% CI 0.36-0.67, <i>I</i><sup>2</sup>=99.9%, <i>P</i>&lt;.001), followed by intervention development (RD 0.36, 95% CI 0.23-0.50, <i>I</i><sup>2</sup>=100.0%, <i>P</i>&lt;.001), intervention implementation (RD 0.35, 95% CI 0.22-0.47, <i>I</i><sup>2</sup>=99.8%, <i>P</i>&lt;.001), and data collection (RD 0.34, 95% CI 0.19-0.50, <i>I</i><sup>2</sup>=99.8%, <i>P</i>&lt;.001). The meta-analysis indicated that high community engagement extent yielded the largest effect size (RD 0.49, 95% CI 0.17-0.82, <i>I</i><sup>2</sup>=100.0%, <i>P</i>&lt;.001), followed by moderate community engagement extent (RD 0.45, 95% CI 0.33-0.58, <i>I</i><sup>2</sup>=99.6%, <i>P</i>&lt;.001) and low community engagement extent (RD 0.15, 95% CI 0.05-0.25, <i>I</i><sup>2</sup>=99.2%, <i>P</i>&lt;.001). The meta-analysis revealed that “health service support” demonstrated the largest effect sizes (RD 0.45, 95% CI 0.25-0.65, <i>I</i><sup>2</sup>=99.9%, <i>P</i>&lt;.001), followed by “health education and discussion” (RD 0.39, 95% CI 0.20-0.58, <i>I</i><sup>2</sup>=99.7%, <i>P</i>&lt;.001), “follow-up and reminder” (RD 0.33, 95% CI 0.23-0.42, <i>I</i><sup>2</sup>=99.3%, <i>P</i>&lt;.001), and “social marketing campaigns and community mobilization” (RD 0.24, 95% CI 0.06-0.41, <i>I</i><sup>2</sup>=99.9%, <i>P</i>&lt;.001).

CONCLUSIONS

The results of this meta-analysis supported the effectiveness of community engagement in vaccination promotion with variations in terms of engagement contents and extent. Community engagement required a “fit-for-purpose” approach rather than a “one-size-fits-all” approach to maximize the effectiveness of vaccine promotion.

CLINICALTRIAL

PROSPERO CRD42022339081; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=339081